	US 11,931,334 B2
	Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
Ginger D. Constantine, Malvern, PA (US)
Assigned to PLEOPHARMA, INC., Phoenixville, PA (US)
Filed by PleoPharma, Inc., Phoenixville, PA (US)
Filed on Dec. 9, 2021, as Appl. No. 17/546,874.
Application 17/546,874 is a continuation of application No. 17/244,585, filed on Apr. 29, 2021, granted, now 11,197,846.
Application 17/244,585 is a continuation in part of application No. PCT/US2021/020921, filed on Mar. 4, 2021.
Claims priority of provisional application 62/985,097, filed on Mar. 4, 2020.
Prior Publication US 2022/0273612 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 31/195 (2006.01); A61K 31/353 (2006.01); A61P 25/30 (2006.01)

CPC A61K 31/353 (2013.01) [A61K 31/195 (2013.01); A61P 25/30 (2018.01)]

41 Claims

1. A method of treating cannabis withdrawal syndrome, comprising administering to a patient in need thereof about 6 mg of nabilone and a therapeutically effective amount of gabapentin on a daily basis, wherein the amount of gabapentin administered is about 100-800 mg per day.